A Chinese eye care giant moves into Brazil with a $120 million bet
A Chinese eye care colossus has chosen Brazil as its next frontier, acquiring a meaningful stake in Opty — a platform that has quietly stitched together dozens of regional ophthalmology practices into a national network. The $120 million investment by Aier Eye Hospital Group, one of the world's largest operators of eye clinics, signals both the maturation of Brazil's health care consolidation story and the growing appetite of Asian capital for Latin American medicine. At its heart, this is a wager that a model built on trust — preserving local names, keeping founding physicians as partners — can endure the ambitions of a global giant.
- Aier Eye Hospital Group, a $11 billion Chinese health care operator with 764 facilities across multiple continents, is entering Brazil at scale with a $120 million bet on Opty.
- The deal compresses years of quiet consolidation into a single inflection point: Opty's 80-plus clinics, built through 15 acquisitions over eight years, now have a powerful international backer — and a new set of expectations.
- Patria, the Brazilian investment firm that orchestrated the roll-up since 2017, walks away with 2.5x returns while retaining roughly 50 percent control, threading the needle between exit and continuity.
- Ninety million dollars of the deal flows directly into Opty's treasury, fueling further expansion and raising the stakes for a model that has prided itself on decentralization and physician partnership.
- The central tension now is whether Opty's collaborative, brand-preserving culture — the very thing that attracted Aier — can survive the velocity and discipline that a global consolidator will inevitably demand.
A Chinese eye care giant is moving into Brazil. Aier Eye Hospital Group, listed in Shenzhen and operating 764 hospitals across China, Europe, Southeast Asia, and the United States, is acquiring a 35 percent stake in Opty, a Brazilian ophthalmology platform, for approximately $120 million. The deal is expected to close within days.
Opty was built by Patria, a Brazilian investment firm that entered the business in late 2017 and spent the following eight years executing a methodical roll-up — completing roughly 15 acquisitions and bringing more than 80 clinics and hospitals under one roof, while deliberately preserving their regional names and keeping founding physicians as active shareholders. Last year the company generated around 1.2 billion reais in revenue, growing at roughly 15 percent annually. Aier's investment values Opty at approximately 11 times EBITDA.
For Patria, the transaction is a clean vindication: returns of about 2.5 times its original capital. Of the $120 million, roughly $90 million flows into Opty's treasury to fund expansion, while $30 million allows Patria to partially monetize its position — retaining around 50 percent ownership. The physician-founders, who collectively hold about 15 percent, will remain as shareholders and participants in governance.
Aier itself reported $3.1 billion in revenue and $453 million in net profit last year, though its stock has declined 32 percent over the past twelve months. The company had been exploring expansion beyond Asia, and Brazil — one of the world's largest ophthalmology markets — presented a logical destination. Negotiations began roughly a year ago and at one point included two European groups before Opty's leadership chose Aier.
Nelson Pestana will continue as CEO, and no changes to the executive structure are anticipated. The deeper question is whether the decentralized, physician-first model that Patria constructed can hold its shape under the pressures of rapid international scaling — a question that Brazil's eye care sector will be watching closely.
A Chinese eye care giant is moving into Brazil. Aier Eye Hospital Group, one of the world's largest operators of ophthalmology clinics and hospitals, is acquiring a 35 percent stake in Opty, a Brazilian platform that has spent the last eight years consolidating independent eye care practices across the country. The deal is worth approximately $120 million and is expected to close within days, according to sources familiar with the negotiations.
Opty is controlled by Patria, a Brazilian investment firm that entered the business in late 2017 and has since orchestrated a methodical roll-up strategy. The company has completed roughly 15 acquisitions, bringing more than 80 clinics and hospitals under its umbrella while keeping their regional names and original physician-founders intact as meaningful shareholders. Last year, Opty generated around 1.2 billion reais in revenue and has been growing at approximately 15 percent annually. The Aier investment values the company at roughly 11 times EBITDA.
For Patria, the math works out cleanly. The firm's initial investment from 2017 will have generated returns of about 2.5 times its original capital. Of the $120 million Aier is paying, roughly $90 million will flow into Opty's treasury to fund further expansion. The remaining $30 million allows Patria to cash out a portion of its stake while maintaining control of the company with approximately 50 percent ownership. The physician-founders collectively hold about 15 percent, and they will remain as shareholders and active participants in governance after the deal closes.
Aier itself is a formidable player in global health care. Listed on the Shenzhen stock exchange, the company operates 764 hospitals and specialized centers spread across China, Europe, Southeast Asia, Hong Kong, and the United States. Last year it reported revenue of $3.1 billion and net profit of $453 million. Its market capitalization sits around $11 billion, though the stock has declined 32 percent over the past year. The company has been looking to expand beyond its core Asian markets, and Brazil represents one of the world's largest ophthalmology markets—a logical destination for growth.
The negotiations began roughly a year ago and at one point involved discussions with two European groups. Ultimately, Opty's leadership chose to partner with Aier. The decision marks a significant moment for the Brazilian eye care sector: a major international consolidator is now entering the market at scale, betting that the model Patria built—decentralized operations, preserved local brands, physician ownership—can work under Chinese stewardship.
Nelson Pestana will continue as CEO with no changes anticipated to the executive structure. The physicians who founded the acquired clinics will remain as shareholders and maintain meaningful roles in how the company operates. Whether that collaborative structure survives the pressures of rapid scaling under new ownership remains an open question. For now, Aier is signaling that it intends to preserve what has worked in Brazil while using its capital and global expertise to push the platform forward.
Citações Notáveis
Opty preserved regional brands and kept physician-founders as meaningful shareholders, a model Aier appears committed to maintaining— Sources familiar with the transaction
A Conversa do Hearth Outra perspectiva sobre a história
Why did Aier choose Brazil now, and why Opty specifically?
Brazil is one of the world's largest eye care markets, and Aier needed a foothold there. Opty had already done the hard work of consolidation—bringing 80 clinics under one platform while keeping them locally rooted. That's exactly what Aier needed: a proven model and existing scale.
The physicians stay as shareholders. Isn't that unusual for a Chinese acquisition?
It is. Most consolidators would strip out the founders and impose a uniform structure. But Opty's whole strength is that it kept the doctors invested and in charge of their own operations. Aier seems to understand that if you break that, you break what made the platform valuable in the first place.
Patria is keeping 50 percent control. What does that mean for Aier's actual influence?
Aier is buying a meaningful stake and a seat at the table, but it's not a takeover. Patria remains the controlling shareholder. It's a partnership, not a replacement. That's probably intentional—Aier gets exposure to the Brazilian market without the full burden of running it alone.
The stock has fallen 32 percent in a year. Is Aier buying at a weak moment?
Possibly. But for Aier, this isn't about stock price—it's about entering a new geography with an established platform. The valuation at 11 times EBITDA is reasonable for a growing health care business. The real test is whether they can maintain that 15 percent annual growth rate once they're in the driver's seat.
What happens to the regional brands and local autonomy?
That's the tension nobody's talking about. Aier says it will preserve them, and the physicians will stay involved. But scaling a company usually means standardization. Watch whether Aier respects that decentralized model or gradually pushes toward uniformity. That will tell you whether this partnership actually works.